NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Sep 19 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release regarding a court approval for the launch of Chlorantraniliprole (CTPR) and its formulations. The Delhi High Court has allowed NATCO to proceed with the launch using a non-infringing process. NATCO is the first company in India to receive registration approval for the indigenous manufacture of CTPR. NATCO plans to launch its products shortly following this approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases